VENETOCLAX

Information current as at: 1 August 2022

Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Venclexta®
Pharmaceutical company:
AbbVie Pty Ltd
Condition/indication:
(therapeutic use)
  • Acute myeloid leukaemia
PBAC Submission type:
Change to listing (Resubmission)
Comment:
--
Related medicines:

Progress Details

Submission received for:
July 2021 PBAC meeting
Opportunity for consumer comment:
Open 21/03/2021 and close 26/05/2021 (see PBS Website)
PBAC meeting:
Held on 07/07/2021
PBAC outcome published:
Recommended (see PBAC Outcomes)
Notice of intent submitted:
06/08/2021
Lodgement of required documentation:
13/08/2021
Acceptance of complete documentation:
Accepted
Agreement to listing arrangements:
Commenced on 27/08/2021
Status:
Finalised
Government processes:
Commenced on 20/09/2021
Medicine listed on the PBS:
01/12/2021 (see PBS schedule)

Case ID: a382

Page last updated: 30 November 2021

v0.9.16